menopause and hormone therapy

in review 5 min read Updated 2026-11-19
menopause and hormone therapy

Menopause is a clinical diagnosis (12 months of amenorrhoea without another cause; average age ~51–52 y) — routine FSH testing is unnecessary in typical midlife women. Menopausal hormone therapy (MHT) is the most effective treatment for bothersome vasomotor symptoms (VMS) and prevents bone loss; the benefit–risk profile is favourable when initiated <60 years of age or <10 years since menopause without contraindications. Give oestrogen + progestogen if the uterus is intact (oestrogen alone after hysterectomy), prefer transdermal oestradiol when VTE/metabolic risk is elevated, and prescribe hormone replacement until ~age 52 for premature ovarian insufficiency (<40 y) or early menopause (<45 y).


diagnosis and primary ovarian insufficiency

  • Natural menopause: diagnosed clinically after 12 consecutive months of amenorrhoea in women ≥45 years; check replicate FSH + oestradiol only when menopausal status is uncertain (e.g., post-hysterectomy, levonorgestrel IUS, or suspected early/premature ovarian failure)
  • Primary ovarian insufficiency (POI) (loss of ovarian function <40 years) and early menopause (<45 years):
    • Confirm with elevated FSH (>25–40 IU/L on two occasions ≥4 weeks apart) + low oestradiol (after excluding pregnancy, hyperprolactinaemia, PCOS, and thyroid disease)
    • Workup for POI: karyotype (Turner syndrome / mosaicism), FMR1 premutation (Fragile X — especially with family history of intellectual disability/ataxia), 21-hydroxylase (anti-adrenal) antibodies (screen for adrenal insufficiency), anti-TPO antibodies, and baseline BMD
    • Management (SOGC 2021; NAMS 2022): offer systemic hormone therapy (or combined OCP if contraception is desired, since ~5–10% can spontaneously ovulate) at least until the average age of natural menopause (~52 years) to protect bone, cardiovascular, and cognitive health

menopausal hormone therapy (SOGC 422a; NAMS 2022; ES 2015)

indications, timing, and duration

  • Indications: moderate–severe vasomotor symptoms (VMS) (hot flushes, night sweats), genitourinary syndrome of menopause (GSM) (low-dose vaginal oestrogen preferred if isolated GSM), POI / early menopause (<45 y), and prevention of osteoporosis / fracture in younger postmenopausal women at elevated risk
  • Do NOT use MHT solely for primary or secondary prevention of coronary heart disease, stroke, or dementia (initiating >65 y increases dementia risk)
  • Favourable initiation window: age <60 years OR <10 years post-menopause without contraindications; starting ≥10 years after menopause or >60 years carries higher absolute risks of CHD, stroke, VTE, and dementia
  • Duration: no mandatory stopping age or fixed 5-year limit (SOGC 2021; NAMS 2022) — re-evaluate benefits and evolving personal risks annually; stopping can be abrupt or tapered (similar recurrence rates)

contraindications and route selection

categoryconditions
absolute contraindications to systemic MHThistory of breast cancer (or oestrogen-sensitive malignancy), coronary heart disease / MI, stroke / TIA, history of VTE (DVT/PE) or high-risk thrombophilia, unexplained vaginal bleeding, active liver disease
cautions (favour transdermal or non-hormonal)moderate CVD risk, diabetes, hypertension, obesity, smoking, hypertriglyceridaemia (>4.5 mmol/L — avoid oral oestrogen), active gallbladder disease, migraine with aura
  • Uterus intact → MUST add endometrial protection:
    • Combined oestrogen + progestogen (EPT): continuous (daily oestrogen + daily progestogen, e.g., micronised progesterone 100 mg PO nightly or MPA 2.5 mg daily — >75% amenorrhoeic by 12 mo) or cyclic (daily oestrogen + progestogen 12–14 days/month, e.g., micronised progesterone 200 mg or MPA 5 mg; preferred in perimenopause)
    • Alternative uterine protection: 52-mg levonorgestrel IUS + systemic oestrogen, TSEC (conjugated oestrogens 0.45 mg + bazedoxifene 20 mg — no progestogen needed), or tibolone (avoid in breast cancer)
  • Post-hysterectomy → oestrogen alone (ET): more favourable breast-cancer and safety profile than combined EPT
  • Transdermal vs oral oestradiol: transdermal oestradiol (patch 25–50 µg, gel) bypasses hepatic first-pass metabolism → lower risk of VTE, stroke, hypertriglyceridaemia, and gallstones, and does not raise TBG (no levothyroxine dose adjustment needed). Preferred in women with elevated VTE risk, obesity, diabetes, or elevated triglycerides (ES 2015; NAMS 2022)
  • Compounded “bioidentical” hormones: recommend against custom-compounded preparations (unregulated dosing, safety, and endometrial protection); use Health Canada–approved micronised 17β-oestradiol and micronised progesterone instead
  • Postmenopausal bleeding: always investigate promptly to exclude endometrial hyperplasia/cancer (even if on MHT or vaginal oestrogen)

genitourinary syndrome of menopause (GSM)

  • First-line: regular vaginal moisturisers (≥2×/week) + vaginal lubricants for intercourse
  • Second-line (if symptoms persist): low-dose vaginal oestrogen (17β-oestradiol tablets/ovules/ring, conjugated oestrogen cream, oestrone cream) — minimal systemic absorption, no progestogen required for endometrial protection, and no demonstrated increase in VTE, stroke, or breast cancer risk
  • Alternatives: vaginal prasterone (DHEA) ovules or oral ospemifene (SERM — avoid in VTE or oestrogen-dependent cancer)
  • History of breast cancer: start with non-hormonal moisturisers/lubricants; if refractory, low-dose vaginal oestrogen or DHEA may be considered via shared decision-making with the oncologist (greater caution if taking aromatase inhibitors)

non-hormonal therapies for vasomotor symptoms (NAMS 2023; SOGC 422a)

Offer when systemic MHT is contraindicated or declined:

  • Recommended evidence-based pharmacotherapy (NAMS 2023):
    • SSRIs / SNRIs (Level I): venlafaxine (37.5–150 mg/d), desvenlafaxine (100–150 mg/d), escitalopram (10–20 mg/d), citalopram (10–20 mg/d), or paroxetine (7.5–25 mg/d — avoid paroxetine/fluoxetine in women taking tamoxifen due to CYP2D6 inhibition; prefer venlafaxine, desvenlafaxine, or citalopram/escitalopram)
    • Gabapentin (Level I): 900–2400 mg/d in divided doses (start 100–300 mg at bedtime — especially useful for night sweats/insomnia)
    • Fezolinetant (Level I; 45 mg PO daily): first-in-class neurokinin-3 (NK3) receptor antagonist blocking NKB signalling at hypothalamic KNDy neurons (rare elevation of hepatic transaminases — monitor baseline/periodic LFTs per product labelling)
    • Oxybutynin (Levels I–II): 2.5–5 mg BID or up to 15 mg ER daily (effective, but caution in older adults due to anticholinergic burden and cognitive decline)
  • Recommended non-pharmacologic (NAMS 2023): cognitive behavioural therapy (CBT), clinical hypnosis, and weight loss
  • NOT recommended for VMS (NAMS 2023): clonidine (high adverse effects, limited efficacy), pregabalin, suvorexant, black cohosh, soy/isoflavones, evening primrose oil, vitamin E, cannabinoids, acupuncture, or paced respiration

Prepared 2026-11-19. Not yet verified — check every number against the sources.

Key references

+1 more source

Suggest a correction menopause and hormone therapy